Risk assessment
• Risk assessment in AML includes the patient's age, the initial leucocyte count, the AML subtype, karyotype data and medical conditions in the patient's history that may affect the feasibility of intensive chemotherapy. 
Treatment plan
• Treatment is divided into induction and consolidation chemotherapy. Whenever possible treatment should be planned with a curative intent. Candidates for allogeneic stem cell transplantation should be identified early during induction. Patients with poor performance status and considerable co-morbidity, as well as elderly patients not eligible for curative treatment, should receive supportive care.
• Whenever possible AML treatment should be in clinical trials and in centres offering a multidisciplinary approach. Such centres should provide an adequate infrastructure including a full haematology and medical oncology service, close collaboration with a bone marrow transplant unit as well as an infectious disease unit and an adequate transfusion service.
Induction chemotherapy
• Chemotherapy should be postponed until satisfactory material for all diagnostic tests has been harvested. Patients with excessive leucocytosis at presentation may require emergency leucapheresis prior to induction chemotherapy. 
Response evaluation
• Response to induction is monitored through clinical examination, serial peripheral blood counts and bone marrow aspirates. During induction-induced aplasia a bone marrow aspirate should be obtained to monitor for early marrow response or leukaemic blast persistence. The usual requirements of AML remission are a normal cellularity of the bone marrow, morphologically normal haematopoiesis and blast levels <5% at evaluation of bone marrow smears [B] .
Follow-up
• Patients are followed clinically with haematological examination to detect early relapse. Serial bone marrow examination is of uncertain value in remission patients without any clinical or haematological evidence of relapse.
Note

Levels of Evidence [I-V] and Grades of Recommendation [A-D]
as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were considered justified standard clinical practice by the expert authors and the ESMO Faculty.
